Skip to content
10-Q

Quarterly Report

Sunshine Biopharma Inc. SBFM SBFMW

0001683168-26-003819

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 5.01M sh
Capex Q1 2026 · Mar 31, 2026 $5.13K
Capex Q1 2026 · Mar 31, 2025 $7.49K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.07M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$1.7M
Stockholders Equity Q1 2026 · Mar 31, 2026 $21.52M
Stockholders Equity Q1 2026 · Dec 31, 2025 $23.04M
Stockholders Equity Q1 2026 · Mar 31, 2025 $22.7M
Stockholders Equity Q1 2026 · Dec 31, 2024 $23.5M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.88M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.44M
Total Liabilities Q1 2026 · Mar 31, 2026 $6.41M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.04M
Current Assets Q1 2026 · Mar 31, 2026 $24.78M
Current Assets Q1 2026 · Dec 31, 2025 $26.85M
Total Assets Q1 2026 · Mar 31, 2026 $27.93M
Total Assets Q1 2026 · Dec 31, 2025 $30.08M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.25
Eps Basic Q1 2026 · Mar 31, 2025 −$0.44
Sga Expense Q1 2026 · Mar 31, 2026 $3.58M
Sga Expense Q1 2026 · Mar 31, 2025 $4.03M
Rd Expense Q1 2026 · Mar 31, 2026 $31.72K
Rd Expense Q1 2026 · Mar 31, 2025 $215.28K
Net Income Q1 2026 · Mar 31, 2026 −$1.24M
Net Income Q1 2026 · Mar 31, 2025 −$1.18M
Operating Income Q1 2026 · Mar 31, 2026 −$1.4M
Operating Income Q1 2026 · Mar 31, 2025 −$1.3M
Gross Profit Q1 2026 · Mar 31, 2026 $2.18M
Gross Profit Q1 2026 · Mar 31, 2025 $2.73M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $5.91M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $6.17M
Revenue Q1 2026 · Mar 31, 2026 $8.09M
Revenue Q1 2026 · Mar 31, 2025 $8.9M